- Alternative Medicine Bone and Joint Disorders Cancer Children's Health Chronic Pain
- Clinical Trials Digestive Disorders Endocrine Issues Genetic Disorders Geriatric Care Healthcare Issues Heart Problems
- Infectious disease Medical Breakthroughs Men's Health Mental Health Neurological Conditions Nutrition
- Oral Health Reproductive Health Respiratory Conditions Skin Conditions Surgery
- Vision and Hearing Women's Health
News from ASH: Updates on CML
Listen to Program
Download Audio MP3
Read Program Transcript Download Transcript PDF
Share this Program
Take Our Survey
- Oregon Health & Science University
For this special webcast, Andrew broadcasts from the 50th annual meeting of the American Society of Hematology (ASH), a meeting that brings experts from all over the world to share information on the latest advances in research for blood cancers and blood related disorders. This program focuses on CML or chronic myelogenous leukemia, featuring guest expert Dr. Michael Deininger. Dr. Deininger is Associate Professor of Hematology/Medical Oncology at Oregon Health & Science University, where he specializes in cancer and blood disorders. Dr. Deininger shares late-breaking news in CML from the ASH meeting.
The discussion begins with talk of the approved medications for CML, most notably Gleevec. Dr. Deininger comments on data being released for first-line and second-line treatments for the disease. He also talks about alternative options for patients who have not had success with Gleevec, or when Gleevac stops working. Dr. Deininger addresses drug resistance, and what the options are when resistance occurs.
Regarding progress being made in finding a cure, Dr. Deininger speaks about the intricacies of what ‘cure’ really means and what this means in relation to CML. He details various factors involved in curing the disease, sharing information about recent studies and immunological control. If you or someone you know is seeking care for CML, this program can be a useful resource in your research.
Get Email Updates:
Privacy Policy
|
Michael Deininger, M.D., Ph.D.
Chief of Hematology and Hematologic Malignancies , University of Utah, Huntsman Cancer Institute
Michael Deininger, MD, PhD, is chief of Hematology and Hematologic Malignancies for Huntsman Cancer Institute (HCI) at the University of Utah. He is a professor in the Department of Medicine at the University of Utah. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly...
more >
|
|
|
National Comprehensive Cancer Network (NCCN)
About : Contact : Editorial Independence : Privacy Policy : Terms of Use
©2005 - 2013 Patient Power, LLC : Site by SiteWeld
 | We comply with the HONcode standard for trustworthy health information: verify here. Last Updated: 10/15/2010 |
